{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:06:49Z","timestamp":1791860809262,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1124\/dmd.123.001499","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:40:17Z","timestamp":1708537217000},"page":"1196-1200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing Trends in Cytokine\u2013CYP Drug Interactions and Relevance to Drug Dosing"],"prefix":"10.1016","volume":"52","author":[{"given":"Aarti","family":"Sawant-Basak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damilola","family":"Olabode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick","family":"Vishwanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001499_bib1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001499_bib2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.123.001499_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","article-title":"Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit","volume":"41","author":"Barr","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1124\/dmd.123.001499_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.13459","article-title":"Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure","volume":"84","author":"Brussee","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.123.001499_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/hon.15_2879","article-title":"Glofitamab step-up dosing: updated efficacy data show high complete response rates in heavily pretreated relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL) patients","volume":"39","author":"Carlo-Stella","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1124\/dmd.123.001499_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7137900","article-title":"Potential pathophysiological mechanisms underlying multiple organ dysfunction in cytokine release syndrome","volume":"2022","author":"Chen","year":"2022","journal-title":"Mediators Inflamm"},{"key":"10.1124\/dmd.123.001499_bib8","article-title":"Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically based pharmacokinetic modeling","author":"Chen","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib9","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001499_bib10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cpt.2814","article-title":"Therapeutic protein drug interactions: a white paper from the International Consortium for Innovation and Quality in Pharmaceutical Development","volume":"113","author":"Coutant","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001499_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/jcph.1093","article-title":"Disease\u2013drug interactions in inflammatory states via effects on CYP-mediated drug clearance","volume":"58","author":"Coutant","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13318-020-00668-8","article-title":"Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients","volume":"46","author":"Deb","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.123.001499_bib13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1124\/dmd.113.052225","article-title":"Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper","volume":"41","author":"Evers","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001499_bib14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"New Eng J Med"},{"key":"10.1124\/dmd.123.001499_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cyto.2013.12.009","article-title":"Cytokine release assays: current practices and future directions","volume":"66","author":"Finco","year":"2014","journal-title":"Cytokine"},{"key":"10.1124\/dmd.123.001499_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejcb.2012.01.003","article-title":"Cytokines and inflammation","volume":"91","author":"Floege","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"10.1124\/dmd.123.001499_bib17","series-title":"Clinical Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry","year":"2020"},{"key":"10.1124\/dmd.123.001499_bib18","series-title":"Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry","year":"2023"},{"key":"10.1124\/dmd.123.001499_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/dmd.123.001499_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1124\/dmd.123.001499_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.46497\/ArchRheumatol.2020.7579","article-title":"Spontaneous spinal epidural hematoma during simultaneous tocilizumab and warfarin use in a patient with rheumatoid arthritis: is there a drug interaction between tocilizumab and oral anticoagulants?","volume":"35","author":"G\u00fcne\u015f","year":"2020","journal-title":"Arch Rheumatol"},{"key":"10.1124\/dmd.123.001499_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/clpt.2014.143","article-title":"Cancer, inflammation, and therapy: effects on cytochrome P450-mediated drug metabolism and implications for novel immunotherapeutic agents","volume":"96","author":"Harvey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001499_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1124\/dmd.123.001499_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2009.308","article-title":"Therapeutic protein-drug interactions and implications for drug development","volume":"87","author":"Huang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001499_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1208\/s12248-016-9890-5","article-title":"Development of a physiologically based pharmacokinetic model to predict disease-mediated therapeutic protein-drug interactions: modulation of multiple cytochrome P450 enzymes by interleukin-6","volume":"18","author":"Jiang","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/dmd.123.001499_bib26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1208\/s12248-013-9495-1","article-title":"Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium\/FDA workshop","volume":"15","author":"Kenny","year":"2013","journal-title":"AAPS J"},{"key":"10.1124\/dmd.123.001499_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40262-018-0730-x","article-title":"Lack of effect of 12-week treatment with risankizumab on the pharmacokinetics of cytochrome P450 probe substrates in patients with moderate to severe chronic plaque psoriasis","volume":"58","author":"Khatri","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001499_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics"},{"key":"10.1124\/dmd.123.001499_bib29","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1124\/dmd.111.040808","article-title":"How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential","volume":"39","author":"Kraynov","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001499_bib30","article-title":"Cytokines: from clinical significance to quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1124\/dmd.123.001499_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease\u2013drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001499_bib32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cpt.985","article-title":"Rapid advances in immunotherapy to treat cancer","volume":"103","author":"McCune","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001499_bib32a","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.ccm.0000807360.97307.75","article-title":"259: Pharmacokinetic influence of tocilizumab on midazolam in critically ill patients with COVID-19","volume":"50","author":"Mefford","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1124\/dmd.123.001499_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153712","article-title":"Cascade of immune mechanism and consequences of inflammatory disorders","volume":"91","author":"Megha","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1124\/dmd.123.001499_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0006-2952(93)90078-B","article-title":"Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo. Independence from the hypothalamo-pituitary axis","volume":"45","author":"Morgan","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.123.001499_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bcp.14668","article-title":"Pharmacokinetics under the COVID-19 storm","volume":"89","author":"Pilla Reddy","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00063030-199809050-00004","article-title":"Drug-cytokine interactions: mechanisms and clinical implications","volume":"9","author":"Reiss","year":"1998","journal-title":"BioDrugs"},{"key":"10.1124\/dmd.123.001499_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.2290","article-title":"Safety, tolerability, and pharmacokinetics of FAAH inhibitor BIA 10-2474: a double-blind, randomized, placebo-controlled study in healthy volunteers","volume":"111","author":"Rocha","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001499_bib39","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/DDDT.S113683","article-title":"Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy","volume":"11","author":"Roman","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/dmd.123.001499_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-immunol-032414-112056","article-title":"Heterogeneity of human CD4+ T cells against microbes","volume":"34","author":"Sallusto","year":"2016","journal-title":"Annu Rev Immol"},{"key":"10.1124\/dmd.123.001499_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jcph.1744","article-title":"Therapeutic protein drug interaction potential in subjects with psoriasis: an assessment based on population pharmacokinetic analyses of sensitive cytochrome P450 probe substrates","volume":"61","author":"Sathe","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","article-title":"Disease\u2013drug\u2013drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis","volume":"89","author":"Schmitt","year":"2011","journal-title":"Clin Pharamcol Ther"},{"key":"10.1124\/dmd.123.001499_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00280-020-04181-2","article-title":"Involvement of cytochrome P450 enzymes in inflammation and cancer: a review","volume":"87","author":"Stipp","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib44","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.123.001499_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"10.1124\/dmd.123.001499_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313009","article-title":"Pathogenesis and treatment of cytokine storm induced by infectious diseases","volume":"22","author":"Tang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001499_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V128.22.651.651","article-title":"Creation of the first non-human primate model that faithfully recapitulates chimeric antigen receptor (CAR) T cell-mediated cytokine release syndrome (CRS) and neurologic toxicity following B cell-directed CAR-T cell therapy","volume":"128","author":"Taraseviciute","year":"2016","journal-title":"Blood"},{"key":"10.1124\/dmd.123.001499_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","article-title":"Inflammation and organ failure severely affect midazolam clearance in critically ill children","volume":"194","author":"Vet","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/dmd.123.001499_bib49","first-page":"48","article-title":"The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders","volume":"27","author":"Wu","year":"2019","journal-title":"Yao Wu Shi Pin Fen Xi"},{"key":"10.1124\/dmd.123.001499_bib50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/psp4.12003","article-title":"Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity","volume":"4","author":"Xu","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001499_bib51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/cts.13507","article-title":"Assessment of the drug-drug interaction potential for therapeutic proteins with pro-inflammatory activities","volume":"16","author":"Yu","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.123.001499_bib52","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jcph.561","article-title":"Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase I study in patients with rheumatoid arthritis using a cocktail approach","volume":"55","author":"Zhuang","year":"2015","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624119927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624119927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:55:46Z","timestamp":1743652546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624119927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0090955624119927"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001499","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Trends in Cytokine\u2013CYP Drug Interactions and Relevance to Drug Dosing","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}